Advertisement

Topics

Stoke Therapeutics to Present Research Supporting Advancement of Dravet Syndrome Program at Annual Meeting of the Oligonucleotide Therapeutics Society

07:00 EDT 27 Sep 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Stoke Therapeutics, Inc. will present research at the upcoming annual meeting of the Oligonucleotide Therapeutics Society supporting its approach of leveraging antisense oligonucleotides to increase protein expression for...

Other Sources for this Article

Ten Bridge Communications
Stephanie Simon, 617-581-9333
stephanie@tenbridgecommunications.com

NEXT ARTICLE

More From BioPortfolio on "Stoke Therapeutics to Present Research Supporting Advancement of Dravet Syndrome Program at Annual Meeting of the Oligonucleotide Therapeutics Society"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...